抗生素风险天数调整应答(RADAR):优化抗生素使用策略比较新方法的评估
该研究在β-内酰胺单药治疗非劣效于氟喹诺酮单药治疗中重度社区获得性肺炎的试验中评估RADAR统计量。RADAR将临床结局与抗生素使用联合排名,结果显示β-内酰胺组RADAR为60.3%(95%CI 57.9%-62.7%,五分类)和58.4%(95%CI 56.0%-60.9%,八分类),均 favoring β-内酰胺;RADAR所需样本量更少但对不良结局敏感性低于传统非劣效分析。
要点
- RADAR在社区获得性肺炎试验中 favoring β-内酰胺而非氟喹诺酮。
- RADAR所需样本量少于传统非劣效分析。
- RADAR对死亡率增加的敏感性低于传统非劣效分析。
核心结论
- RADAR favoring β-内酰胺优于氟喹诺酮治疗社区获得性肺炎。
- RADAR所需样本量少于传统非劣效分析,但对不良结局敏感性较低。
研究设计与样本
- 基于一项非劣效试验,β-内酰胺单药组n=656,氟喹诺酮单药组n=888,患者为中重度社区获得性肺炎。
- 患者按临床结局(五或八分类)和抗生素使用排名,计算β-内酰胺组排名优于氟喹诺酮组的概率。
- 模拟β-内酰胺组90天死亡率增加,进行RADAR和非劣效分析。
主要发现
- β-内酰胺组相比氟喹诺酮组的RADAR为60.3%(95%CI 57.9%-62.7%,五分类)和58.4%(95%CI 56.0%-60.9%,八分类),均 favoring β-内酰胺。
- RADAR所需样本量为非劣效样本量计算的38%(250/653,五分类)和89%(580/653,八分类)。
- 模拟死亡率下,传统分析中β-内酰胺组在相对风险1.125时失去非劣效性;RADAR在相对风险1.25(八分类)和1.5(五分类)时失去优效性。
临床怎么用
- RADAR可用于抗生素管理策略比较试验,提高效率但需注意其对不良结局敏感性较低。
局限性
- RADAR对 detrimental 临床结局的敏感性低于传统非劣效分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Response Adjusted for Days of Antibiotic Risk (RADAR) statistic was proposed to improve the efficiency of trials comparing antibiotic stewardship strategies to optimize antibiotic use. We studied the behaviour of RADAR in a non-inferiority trial in which a β-lactam monotherapy strategy (n = 656) was non-inferior to fluoroquinolone monotherapy (n = 888) for patients with moderately severe community-acquired pneumonia. METHODS: Patients were ranked according to clinical outcome, using five or eight categories, and antibiotic use. RADAR was calculated as the probability that the β-lactam group had a more favourable ranking than the fluoroquinolone group. To investigate the sensitivity of RADAR to detrimental clinical outcome we simulated increasing rates of 90-day mortality in the β-lactam group and performed the RADAR and non-inferiority analysis. RESULTS: The RADAR of the β-lactam group compared with the fluoroquinolone group was 60.3% (95% CI 57.9%-62.7%) using five and 58.4% (95% CI 56.0%-60.9%) using eight clinical outcome categories, all in favour of β-lactam. Sample sizes for RADAR were 38% (250/653) and 89% (580/653) of the non-inferiority sample size calculation, using five or eight clinical outcome categories, respectively. With simulated mortality rates, loss of non-inferiority of the β-lactam group occurred at a relative risk of 1.125 in the conventional analysis, whereas using RADAR the β-lactam group lost superiority at a relative risk of mortality of 1.25 and 1.5, with eight and five clinical outcome categories, respectively. CONCLUSIONS: RADAR favoured β-lactam over fluoroquinolone therapy for community-acquired pneumonia. Although RADAR required fewer patients than conventional non-inferiority analysis, the statistic was less sensitive to detrimental outcomes.
引用
- Schweitzer VA, van Smeden M, Postma DF, et al. Response Adjusted for Days of Antibiotic Risk (RADAR): evaluation of a novel method to compare strategies to optimize antibiotic use. Clin Microbiol Infect. 2017. PMID: 28501668. doi:10.1016/j.cmi.2017.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。